Good company with great development opportunities - Engineering Specialist Merck Employee Review

5.0
Feb 7, 2019
Recommend
CEO approval
Business Outlook

Pros

If you perform you will be noticed. Top performers receive good bonuses. Good employee development and promotion opportunities. Huge company means you have ability to dictate your path whatever that may be. Diverse working environment Good for entry level graduates. Given a lot of responsibility quickly. Company is actually ethical and interested in helping people - can't be said for all of big pharma. Solid drug pipeline and strong growth of current drugs = stability.

Cons

Good employee development means a lot of internal movement which can make things difficult. Despite being rewarding for high performers, poor or incompetent individuals are rarely fired. This means useless bodies clogging up higher individual contributer positions.If youre lazy I suppose you could call this a pro.... Some systems have gotten too bureaucratic making process improvement difficult at times. Big company means some people you interact with / rely on are not in your reporting structure. This can make it difficult to resolve delays or problems with these people.

Explore other reviews about Merck

5.0
Jul 12, 2026
Recommend
CEO approval
Business Outlook

Pros

Work Life Balance, Benefits, Remote Work

Cons

Easy to stagnate if not being proactive about building skills and networking

4.0
Jun 30, 2026
Recommend
CEO approval
Business Outlook

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Cons

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

See reviews by: Helpful|Rating|Date|All